"it must be assumed that ZEL is to be sold lock, stock and barrel and will not be listed on an exchange! And it will probably make no difference what we value the asset at,  it was a spin off so I assume 0 dollars is the starting point for appreciation on any disposition."

During the oral presentation (it might have been the Q&A that was also on the webcast) Don stated that it would be pretty simple to sell off just the ZEN-3694 IP since there are only three patents that are linked to ZEN-3694. So tons of IP and patents not associated with the ZEN-3694 IP and patents. There are scenarios where ZEL may still exist in case just ZEN-3694 is sold. Don also talked about regional imminent licensing deals (for ZEN-3694?) and partnering with big pharma on a triple-negative breast cancer trial of ZEN-3694 in combo with PARP inhibitor. Of course, it is all talk until deal is signed and we get an official news release. Lots of potential but I'm not convinced that the plan at this time is to sell ZEL.

BearDownAZ